Who
Alethia Young
Director
Company insider
Files Form 4 as: Director, Pacira BioSciences; Chief Financial Officer, Bicycle Therapeutics; Director, PTC Therapeutics; Chief Financial Officer, LENZ Therapeutics.
In numbers
- Trades disclosed
- 51
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $593K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 1 Apr 2022
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —6,405 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,891 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,891 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —6,405 at $0.00 | filing |
| 5 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K2,456 at $6.45 | filing |
| 5 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K1,878 at $6.54 | filing |
| 5 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K2,456 at $6.45 | filing |
| 5 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K1,878 at $6.54 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,475 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,475 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K3,289 at $6.80 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K3,289 at $6.80 | filing |
| 2 Oct 2025filed 6 Oct 2025 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,823217 at $8.40 | filing |
| 2 Oct 2025filed 6 Oct 2025 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,282265 at $8.61 | filing |
News
Critical Survey: Aktis Oncology (NASDAQ:AKTS) vs. Bicycle Therapeutics (NASDAQ:BCYC)BCYC · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Alethia Young; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.